Design of curcumin loaded cellulose nanoparticles for prostate cancer

Current Drug Metabolism

Volumn 13, Issue 1, 2012, Pages 120-128

  Yallapu, Murali Mohan ^a   Dobberpuhl, Mitch Ray ^a   Maher, Diane Michele ^a   Jaggi, Meena ^a,b   Chauhan, Subhash Chand ^a,b  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

Anti cancer drug; Cancer therapy; Cellulose; Drug delivery systems; Nanomedicine; Nanoparticles

Indexed keywords

BETA CYCLODEXTRIN; CURCUMIN; DENDRIMER; HYDROXYPROPYLMETHYLCELLULOSE; MAGNETIC NANOPARTICLE; POLYGLACTIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CULTURE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG SYNTHESIS; DRUG UPTAKE; HUMAN; HUMAN CELL; MALE; PROSTATE CANCER;

EID: 84857583365     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012798356952     Document Type: Article

References (59)

1. Centers for disease control and prevention, National program of cancer registries (NPCR), 2007 Top ten cancers in United States. http://apps.nccd.cdc. gov/uscs/toptencancers.aspx. (Accessed April 25, 2011
2. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M. J. Cancer statistics, 2009. CA. Cancer J. Clin., 2009, 59, 225-249.
3. Teiten, M.H.; Gaascht, F.; Eifes, S.; Dicato, M.; Diederich, M. Chemopreventive potential of curcumin in prostate cancer. Genes Nutr., 2010, 5, 61-74.
4. Al-Mamgani, A.; Lebesque, J.V.; Heemsbergen, W.D.; Tans, L.; Kirkels, W.J.; Levendag, P.C.; Incrocci, L. Controversies in the treatment of high-risk prostate cancer-what is the optimal combination of hormonal therapy and radiotherapy: A review of literature. Prostate, 2010, 70, 701-709.
5. Dal Pra, A.; Cury, F.L.; Souhami, L. Combining radiation therapy and androgen deprivation for localized prostate cancer-a critical review. Curr Oncol., 2010, 17, 28-38.
6. Kohli, M.; Tindall, D.J. New developments in the medical management of prostate cancer. Mayo Clin. Proc., 2010, 85, 77-86.
7. Moore, C.M.; Pendse, D.; Emberton, M. Photodynamic therapy for prostate cancer-a review of current status and future promise. Nat. Clin. Pract. Urol., 2009, 6, 18-30.
8. Peschel, R.E.; Robnett, T.J.; Hesse, D.; King, C.R.; Ennis, R.D.; Schiff, P.B.; Wilson, L.D. PSA based review of adjuvant and salvage radiation therapy vs. observation in postoperative prostate cancer patients. Int. J. Cancer., 2000, 90, 29-36. (Pubitemid 30158974)
9. Quon, H.; Loblaw, D.A. Androgen deprivation therapy for prostate cancer-review of indications in 2010. Curr. Oncol., 2010, 17, S38-44.
10. Roscigno, M.; Sangalli, M.; Mazzoccoli, B.; Scattoni, V.; Da Pozzo, L.; Rigatti, P. Medical therapy of prostate cancer. A review. Minerva Urol. Nefrol., 2005, 57, 71-84. (Pubitemid 40979455)
11. Beer, T.M.; Bubalo, J.S. Complications of chemotherapy for prostate cancer. Semin. Urol. Oncol., 2001, 19, 222-230. (Pubitemid 32816502)
12. Heidenreich, A.; von Knobloch, R.; Hofmann, R. Current status of cytotoxic chemotherapy in hormone refractory prostate cancer. Eur. Urol., 2001, 39, 121-130. (Pubitemid 32171177)
13. Pomerantz, M.; Kantoff, P. Advances in the treatment of prostate cancer. Annu. Rev. Med., 2007, 58, 205-220. (Pubitemid 46706510)
14. Rauchenwald, M.; De Santis, M.; Fink, E.; Holtl, W.; Kramer, G.; Marei, I.C.; Neumann, H.J.; Reissigl, A.; Schmeller, N.; Stackl, W.; Hobisch, A.; Krainer, M. Chemotherapy for prostate cancer. Wien. Klin. Wochenschr., 2008, 120, 440-449.
15. Amato, R.J.; Teh, B.S.; Henary, H.; Khan, M.; Saxena, S. A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate. Urol. Oncol., 2009, 27, 165-169.
16. Letsch, M.; Schally, A.V.; Szepeshazi, K.; Halmos, G.; Nagy, A. Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238. J. Urol., 2004, 171, 911-915. (Pubitemid 38090532)
17. Small, E.J. Advances in prostate cancer. Curr. Opin. Oncol., 1999, 11, 226-235. (Pubitemid 29229619)
18. Fitzpatrick, J.M. The application of nanotechnology for the treatment of metastatic prostate cancer. BJU Int. 2009, 104, page (i
19. Gommersall, L.; Shergill, I.S.; Ahmed, H.U.; Arya, M.; Grange, P.; Gill, I.S. Nanotechnology in the management of prostate cancer. BJU Int., 2008, 102, 1493-1495.
20. Michael, A.; Syrigos, K.; Pandha, H. Prostate cancer chemotherapy in the era of targeted therapy. Prostate Cancer Prostatic. Dis., 2009, 12, 13-16.
21. Kuttan, R.; Sudheeran, P.C.; Josph, C.D. Turmeric and curcumin as topical agents in cancer therapy. Tumori., 1987, 73, 29-31. (Pubitemid 17034485)
22. Shishodia, S.; Chaturvedi, M.M.; Aggarwal, B.B. Role of curcumin in cancer therapy. Curr. Probl. Cancer., 2007, 31, 243-305. (Pubitemid 47077491)
23. Thangapazham, R.L.; Puri, A.; Tele, S.; Blumenthal, R.; Maheshwari, R.K. Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int. J. Oncol., 2008, 32, 1119-1123.
24. Anand, P.; Sundaram, C.; Jhurani, S.; Kunnumakkara, A.B.; Aggarwal, B.B. Curcumin and cancer: An "old-age" disease with an "age-old" solution. Cancer Lett., 2008, 267, 133-164.
25. Hatcher, H.; Planalp, R.; Cho, J.; Torti, F.M.; Torti, S.V. Curcumin: From ancient medicine to current clinical trials. Cell Mol. Life Sci., 2008, 65, 1631-1652.
26. Kunnumakkara, A.B.; Anand, P.; Aggarwal, B.B. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett., 2008, 269, 199-225.
27. Landis-Piwowar, K.R.; Milacic, V.; Chen, D.; Yang, H.; Zhao, Y.; Chan, T.H.; Yan, B.; Dou, Q.P. The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Drug Resist. Update, 2006, 9, 263-273. (Pubitemid 46357634)
28. Page, P.; Yang, L.X. Novel chemoradiosensitizers for cancer therapy. Anticancer Res., 2010, 30, 3675-3682.
29. Yallapu, M.M.; Maher, D.M.; Sundram, V.; Bell, M.C.; Jaggi, M.; Chauhan, S.C. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J. Ovarian Res., 2010, 3, 11.
30. Um, Y.; Cho, S.; Woo, H.B.; Kim, Y.K.; Kim, H.; Ham, J.; Kim, S.N.; Ahn, C.M.; Lee, S. Synthesis of curcumin mimics with multidrug resistance reversal activities. Bioorg. Med. Chem., 2008, 16, 3608-3615. (Pubitemid 351484048)
31. Strimpakos, A.S.; Sharma, R.A. Curcumin: Preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid. Redox Signal, 2008, 10, 511-545.
32. Gosangari, S.L.; Watkin, K.L. Effect of preparation techniques on the properties of curcumin liposomes: Characterization of size, release and cytotoxicity on a squamous oral carcinoma cell line. Pharm. Dev. Technol., 2011 [http://informahealthcare.com/doi/abs/ 10.3109/10837450.2010.522583].
33. Yallapu, M.M.; Gupta, B.K.; Jaggi, M.; Chauhan, S.C. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J. Colloid Interface Sci., 2010, 351, 19-29.
34. Konwarh, R.; Saikia, J.P.; Karak, N.; Konwar, B.K. 'Poly(ethylene glycol)-magnetic nanoparticles-curcumin' trio: Directed morphogenesis and synergistic free-radical scavenging. Colloids Surf. B: Biointerfaces, 2010, 81, 578-586.
35. Bisht, S.; Feldmann, G.; Soni, S.; Ravi, R.; Karikar, C.; Maitra, A.; Maitra, A. Polymeric nanoparticle-encapsulated curcumin (" nanocurcumin"): A novel strategy for human cancer therapy. J. Nanobiotechnology, 2007, 5, 3.
36. Bisht, S.; Mizuma, M.; Feldmann, G.; Ottenhof, N.A.; Hong, S.M.; Pramanik, D.; Chenna, V.; Karikari, C.; Sharma, R.; Goggins, M.G.; Rudek, M.A.; Ravi, R.; Maitra, A.; Maitra, A. Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer. Mol. Cancer Ther., 2010, 9, 2255-2264.
37. Yallapu, M.M.; Jaggi, M.; Chauhan, S.C. Scope of nanotechnology in ovarian cancer therapeutics. J. Ovarian Res., 2010, 3, 19.
38. Yallapu, M.M.; Othman, S.F.; Curtis, E.T.; Gupta, B.K.; Jaggi, M.; Chauhan, S.C. Multi-functional magnetic nanoparticles for magnetic resonance imaging and cancer therapy. Biomaterials, 2011, 32, 1890-1905.
39. Yallapu, M.M.; Jaggi, M.; Chauhan, S.C. beta-Cyclodextrincurcumin self-assembly enhances curcumin delivery in prostate cancer cells. Colloids Surf. B: Biointerfaces, 2010, 79, 113-125.
40. Aggarwal, B.B.; Sung, B. Pharmacological basis for the role of curcumin in chronic diseases: An age-old spice with modern targets. Trends Pharmacol. Sci., 2009, 30, 85-94.
41. Ireson, C.R.; Jones, D.J.; Orr, S.; Coughtrie, M.W.; Boocock, D.J.; Williams, M.L.; Farmer, P.B.; Steward, W.P.; Gescher, A.J. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol. Biomarkers Prev., 2002, 11, 105-111. (Pubitemid 34118319)
42. Ireson, C.; Orr, S.; Jones, D.J.; Verschoyle, R.; Lim, C.K.; Luo, J.L.; Howells, L.; Plummer, S.; Jukes, R.; Williams, M.; Steward, W.P.; Gescher, A. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol esterinduced prostaglandin E2 production. Cancer Res., 2001, 61, 1058-1064. (Pubitemid 32174425)
43. Anand, P.; Kunnumakkara, A.B.; Newman, R.A.; Aggarwal, B.B. Bioavailability of curcumin: Problems and promises. Mol. Pharm., 2007, 4, 807-818.
44. Shahani, K.; Swaminathan, S.K.; Freeman, D.; Blum, A.; Ma, L.; Panyam, J. Injectable sustained release microparticles of curcumin: A new concept for cancer chemoprevention. Cancer Res., 2010, 70, 4443-4452.
45. Shahani, K.; Panyam, J. Highly loaded, sustained-release microparticles of curcumin for chemoprevention. J. Pharm. Sci., 2011, 100, 2599-2609.
46. Lim, K.J.; Bisht, S.; Bar, E.E.; Maitra, A.; Eberhart, C.G. A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer Biol. Ther., 2011, 11, 464-473.
47. Mulik, R.S.; Monkkonen, J.; Juvonen, R.O.; Mahadik, K.R.; Paradkar, A.R. Transferrin mediated solid lipid nanoparticles containing curcumin: Enhanced in vitro anticancer activity by induction of apoptosis. Int. J. Pharm., 2010, 398, 190-203.
48. Mohanty, C.; Sahoo, S.K. The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials, 2010, 31, 6597-6611.
49. Merisko-Liversidge, E.M.; Liversidge, G.G. Drug nanoparticles: Formulating poorly water-soluble compounds. Toxicol. Pathol., 2008, 36, 43-48.
50. Pridgen, E.M.; Langer, R.; Farokhzad, O.C. Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Nanomedicine, 2007, 2, 669-680. (Pubitemid 350268246)
51. Krishnan, S.; Diagaradjane, P.; Cho, S.H. Nanoparticle-mediated thermal therapy: Evolving strategies for prostate cancer therapy. Int. J. Hyperthermia, 2010, 26, 775-789.
52. Brannon-Peppas, L.; Blanchette, J.O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug. Deliv. Rev., 2004, 56, 1649-1659. (Pubitemid 39177694)
53. Araki, T.; Hayashi, M.; Saruta, T. Anion-exchange blocker enhances cytoplasmic vacuole formation and cell death in serumdeprived mouse kidney epithelial cells in mice. Cell Biol. Int., 2006, 30, 93-100. (Pubitemid 43253733)
54. Brauns, S.C.; Dealtry, G.; Milne, P.; Naude, R.; Van de Venter, M. Caspase-3 activation and induction of PARP cleavage by cyclic dipeptide cyclo(Phe-Pro) in HT-29 cells. Anticancer Res., 2005, 25, 4197-4202. (Pubitemid 41665204)
55. Yang, S.E.; Hsieh, M.T.; Tsai, T.H.; Hsu, S.L. Down-modulation of Bcl-XL, release of cytochrome c and sequential activation of caspases during honokiol-induced apoptosis in human squamous lung cancer CH27 cells. Biochem. Pharmacol., 2002, 63, 1641-1651.
56. Choi, Y.H.; Kong, K.R.; Kim, Y.A.; Jung, K.O.; Kil, J.H.; Rhee, S.H.; Park, K.Y. Induction of Bax and activation of caspases during beta-sitosterol-mediated apoptosis in human colon cancer cells. Int. J. Oncol., 2003, 23, 1657-1662.
57. Mahmoudi, M.; Simchi, A.; Imani, M.; Shokrgozar, M.A.; Milani, A.S.; Hafeli, U.O.; Stroeve, P. A new approach for the in vitro identification of the cytotoxicity of superparamagnetic iron oxide nanoparticles. Colloids Surf. B: Biointerfaces, 2010, 75, 300-309.
58. Anitha, A.; Maya, S.; Deepa, N.; Chennazhi, K.P.; Nair, S.V.; Tamura, H.; Jayakumar, R. Efficient water soluble Ocarboxymethyl chitosan nanocarrier for the delivery of curcumin to cancer cells Carbohyd. Polym., 2011, 83, 452-461.
59. Yadav, V.R.; Prasad, S.; Kannappan, R.; Ravindran, J.; Chaturvedi, M.M.; Vaahtera, L.; Parkkinen, J.; Aggarwal, B. B. Cyclodextrincomplexed curcumin exhibits anti-inflammatory and antiproliferative activities superior to those of curcumin through higher cellular uptake. Biochem. Pharmacol., 2010, 80, 1021-1032.